跳转至内容
Merck
所有图片(1)

主要文件

S5068

Sigma-Aldrich

沙美特罗 羟萘甲酸盐

≥98% (HPLC), solid

别名:

(±) 4-羟基-a1-[[[6-(4-苯基丁氧基)己基]氨基]间-乙基]-1,3-苯二甲醇 羟萘甲酸盐, GR 33343X 羟萘甲酸盐

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C25H37NO4 · C11H8O3
CAS号:
94749-08-3
分子量:
603.75
MDL编号:
MFCD00897708
UNSPSC代码:
12352200
PubChem化学物质编号:
24278713
NACRES:
NA.77

方案

≥98% (HPLC)

表单

solid

颜色

white

溶解性

H2O: slightly soluble
ethanol: slightly soluble
methanol: freely soluble

创始人

GlaxoSmithKline

SMILES字符串

OC(=O)c1ccc2ccccc2c1O.OCc3cc(ccc3O)C(O)CNCCCCCCOCCCCc4ccccc4

InChI

1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)

InChI key

XTZNCVSCVHTPAI-UHFFFAOYSA-N

基因信息

human ... ADRB2(154)

正在寻找类似产品? 访问 产品对比指南

应用

昔萘酸沙美特罗与人血清白蛋白结合用于研究兔的免疫反应。7

生化/生理作用

β2-肾上腺素能受体激动剂。
昔萘酸沙美特罗是一种 β2 型肾上腺素受体激动剂，具有更持久的支气管扩张作用和抗炎作用。它可以放松气道平滑肌、稳定肥大细胞并调节组胺的释放。昔萘酸沙美特罗对轻度哮喘、慢性阻塞性肺疾病特别有效。5,6

特点和优势

该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
MKCV6098
MKCH0814
MKBV7573V
MKBQ2324V
SLBC3795V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Claus Vogelmeier et al.
Respiratory medicine, 107(1), 75-83 (2012-10-30)
The objective of this study was to investigate the effect of tiotropium compared with salmeterol on exacerbations in patients with moderate (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) chronic obstructive pulmonary disease (COPD) and those naïve to
Marc Decramer et al.
Respiratory medicine, 107(2), 223-232 (2012-12-12)
Indacaterol is a once-daily, long-acting β(2)-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are
K F Chung
International journal of chronic obstructive pulmonary disease, 1(3), 235-242 (2007-12-01)
Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate (FP), with a long-acting beta2-agonist, salmeterol (Sal), have demonstrated a greater improvement in lung function and in quality of life measures after the combination compared with either component
Finney, P.A., et al.
British Journal of Pharmacology, 132, 1267-1270 (2001)
Adam Barczyk et al.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 33(196), 187-192 (2013-01-01)
Chronic obstructive pulmonary disease (COPD) is one of the most important diseases because of high and constantly increasing prevalence, morbidity and mortality. An update of the Global strategy for the diagnosis, management, and prevention of COPD - GOLD report was
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门